Slider

Concord established its Branded Generic business in 2016 with the intent to provide safe, effective and efficacious drug products to patients. Concord has vertically integrated from API to Finished products, ensuring that the entire value chain is being manufactured under highest standards of global regulatory compliant environment. Concord is focused on specialty therapeutic segments like Immunology- Organ Transplant, CKD & Critical Care. Our dedicated sales team is having rich experience and is focused on understanding and addressing the unmet needs of the patients in the targeted segments in order to build brand equity with the doctors and patients.


Composition

Each hard gelatin capsule contains Tacrolimus 0.25mg,0.5mg,1mg & 2mg.

Description

Tacrolimus is a macrolide immunosuppressant produced by Streptomyces tsukubaensis. Tacrolimus appears as white crystals or crystalline powder.

Dosage and Administration Kidney Transplantation

The recommended starting oral dose of Tacrolimus (administered every 12 hours in two divided doses) is 0.2 mg/kg/day when used in combination with azathioprine or 0.1 mg/kg/day when used in combination with MMF.

Storage Condition

Store in a cool, dry place, protected from light and moisture.


Composition

Each enteric coated tablet contains Mycophenolic acid (as sodium salt) 180mg, 360mg & 540mg

Description

Mycophenolic acid is an enteric formulation of mycophenolate sodium that delivers the active moiety mycophenolic acid (MPA). It is an immunosuppressive agent.

Indications

Mycophenolate sodium delayed-release tablets are indicated for the prophylaxis of organ rejection in patients receiving allogenic renal transplants administered in combination with other Immunosuppressants.

Dosage and administration Renal Transplantation

Adults:The recommended dose of Mycophenolate sodium is 720mg administered twice daily (1440mg total daily dose) on an empty stomach one hour before or two hours after food intake.

Geriatrics: The maximum recommended dose is 720mg administered twice daily.

Storage

Store in a cool, dry place, protected from light and moisture.


Composition

Each tablet contains Mycophenolate Mofetil - 250mg, 500mg & 750mg

Description

Mycophenolate mofetil is the 2-morpholinoethyl ester of mycophenolic acid (MPA), an immunosuppressive agent; inosine monophosphate dehydrogenase (IMPDH) inhibitor used to prevent rejection in allogenic organ transplant.

Indications

Mycophenolate mofetil is primarily indicated for the prophylaxis of organ rejection in patients receiving allogeneic renal transplants.

Dosage and administration Renal Transplantation

A dose of 1gm administered orally twice a day (daily dose of 2gm), is recommended for use in renal transplant patients.

Use in renal impairment:In renal transplant patients with severe chronic renal impairment (glomerular filtration rate < 25 ml•min-1•1.73 m-2) outside the immediate post-transplant period doses greater than 1gm administered twice a day should be avoided. These patients should also be carefully observed. No dose adjustments are needed in patients experiencing delayed renal graft function post-operatively.

Use in severe hepatic impairment: No dose adjustments are needed for renal transplant patients with severe hepatic parenchymal disease.

Storage

Store in a cool, dry place protected from light and moisture.


Description

Everolimus is an immunosuppressant drug used to prevent rejection in organ transplantation, and is especially useful in kidney transplants.

Composition

Each uncoated /coated tablet contains Everolimus 0.25mg and 0.5mg

Indications and Clinical Use

Everolimus is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk, receiving an allogenic renal or cardiac transplant. Everolimus should be used in combination with cyclosporine and corticosteroids.

Dosage and Administration

Adults: An initial dose regimen of 0.75 mg b.i.d., which is recommended for the general kidney and heart transplant population, should be administered as soon as possible after transplantation.The daily dose of Everolimus should always be given orally in two divided doses (b.i.d.). Patients receiving Everolimus may require dose adjustments based on blood levels achieved, tolerability, individual response, change in co-medications and the clinical situation. Dose adjustments can be made at 4-5 days intervals.

Patients with renal impairment: No dosage adjustment is required.

Storage

Store in a cool, dry place protected from light and moisture.


Composition
Cyclosporine ME 25, 50 & 100mg capsules

Description

Cyclosporine immediately forms a microemulsion in an aqueous environment, is a cyclic polypeptide immunosuppressant agent. It is produced as a metabolite by the fungus species Beauveria nivea.

Indications Solid Organ Transplantation

Cyclosporine is indicated for the prophylaxis of organ rejection in kidney, allogeneic transplants & has been used in combination with other Immunosuppressants.

Dosage and Administration

The daily dose of Cyclosporine should always be given in two divided doses in a day .The initial oral dose of Cyclosporine should be given 4-12 hours prior to transplantation as a single dose of 15mg/kg.

The initial single daily dose is continued post-operatively for 1-2 weeks and then tapered by 5% per week to a maintenance dose of 5-10mg/kg/day. Some centers have successfully tapered the maintenance dose to as low as 3mg/kg/day in selected renal transplant patients without an apparent rise in rejection rate.

Storage

Store in a cool, dry place protected from light and moisture.


Composition

Each film coated tablet contains Valganciclovir hydrochloride IP equivalent to Valganciclovir 450mg

Description

Valganciclovir is a pro-drug of antiviral, after oral administration, is rapidly converted to Ganciclovir by intestinal and hepatic esterases.

Indications:

Prevention of CMV disease in kidney, heart, and kidney-pancreas transplant recipients at high risk (CMV-seronegative recipient / CMV-seropositive donor).

Cytomegalovirus (CMV) Retinitis and secondary prophylaxis of CMV retinitis in HIV infected

Dosage:
Treatment of CMV retinitis

Induction: 900 mg (two 450 mg tablets) twice a day for 21 days

Maintenance: 900 mg (two 450 mg tablets) once a day

Prevention of CMV disease in heart or kidney-pancreas transplant patients 900 mg (two 450 mg tablets) once a day within 10 days of transplantation until 100 days post-transplantation
Prevention of CMV disease in kidney transplant patients 900 mg (two 450 mg tablets) once a day within 10 days of transplantation until 200 days post-transplantation
Pediatric Dosage
Prevention of CMV disease in kidney transplant patients 4 months to 16 years of age Dose once a day within 10 days of transplantation until 200 days post-transplantation according to dosage algorithm
Prevention of CMV disease in heart transplant patients 1 month to 16 years of age Dose once a day within 10 days of transplantation until 100 days post-transplantation according to dosage algorithm
Storage

Store in a cool, dry place protected from light and moisture.

Chronic kidney disease includes conditions that damage your kidneys and decrease their ability to keep you healthy. If kidney disease gets worse, wastes can build to high levels in your blood and make you feel sick. You may develop complications like high blood pressure, anemia (low blood count), weak bones, poor nutritional health and nerve damage. Also, kidney disease increases your risk of having heart and blood vessel disease. These problems may happen slowly over a long period of time. Chronic kidney disease may be caused by diabetes, high blood pressure and other disorders. Early detection and treatment can often keep chronic kidney disease from getting worse. When kidney disease progresses, it may eventually lead to kidney failure, which requires dialysis or a kidney transplant to maintain life.


Composition

SEVECORD- 400 (Each film coated tablet contains: Sevelamer Carbonate 400 mg)

SEVECORD- 800 (Each film coated tablet contains: Sevelamer Carbonate 800 mg)

Initial Recommended Dose of Sevelamer Carbonate
Serum Phosphorus Level in Patients (mg/dL) Total Daily Dose of Sevelamer Carbonate to be Taken Over 3 Meals per Day (g*)
5.5 to 7.5 2.4
7.5 to 9 3.6 to 4.8
≥9 4.8
Indications & Usage

Sevelamer carbonate is indicated in the management of serum phosphorus in patients with chronic kidney disease (CKD) on hemodialysis or peritoneal dialysis and patients with CKD not on dialysis, with serum phosphate levels greater than 5.5 mg/kg.

Sevelamer carbonate is advised be taken 3 times a day with meals. The initial recommended dose of Sevelamer based on the serum phosphate level.

Dosage Titration and Maintenance

Serum phosphorus levels must be monitored and the dose of Sevelamer carbonate titrated every 2 to 4 weeks until an acceptable serum phosphorus level is reached; with regular monitoring thereafter.

Special instructions:

Tablets should be swallowed intact and should not be crushed, chewed, or broken into pieces prior to administration.

Storage conditions

Store in cool & dry place. Keep the medicine out of reach of children


Composition
Each film coated tablet contains:

Alpha-Ketoanalogue of Isoleucine, Cal. salt : 067 mg , Alpha-Ketoanalogue of Leucine, Cal.salt:101 mg, Alpha-Ketoanalogue of Phenylalanine, Cal.salt : 068 mg, Alpha-Ketoanalogue of Valine, Cal.salt : 086 mg Alpha-hydroxyanalogue of Methionine, Cal. : 059 mg ,L-Threonine USP : 053 mg, L-Tryptophan USP : 023 mg, L-Histidine USP : 038 mg ,L-Tyrosine USP : 030 mg

Valolog Sachets
Alpha-Ketoanalogue Powder ( eq. to 3 Tabs ) in Sachet (Mango Flavoured )
Composition
Each Sachet contains:

Alpha-Ketoanalogue of Isoleucine, Calcium salt : 201 mg Alpha-Ketoanalogue of Leucine, Calcium salt : 303 mg Alpha-Ketoanalogue of Phenylalanine, Cal.salt : 204 mg Alpha-Ketoanalogue of Valine, Cal.salt : 258 mg Alpha-hydroxyanalogue of Methionine, Cal.salt : 177 mg L-Lysine acetate USP : 315 mg L-Threonine USP : 159 mg L-Tryptophan USP : 069 mg L-Histidine USP : 114 mg L-Tyrosine USP : 090 mg

Description:

Oral nutritional formulation containing 10 amino acids ; provides all essential amino acids five out of them are keto or hydroxyanalogues that help in reducing Nitrogen load while it promotes muscle protein synthesis.

Indications:

Alpha-keto analogues are beneficial in treatment of uremia as they provide adequate amino acid nutrition while reducing the total nitrogen load; these analogues are converted to amino-acids through transamination by taking amino group from nonessential amino acids and thereby reducing cellular ammonia level.

Adding Ketoanalogue to very low-protein ( 40 g per day) diets for patients with chronic kidney disease (CKD stage I,II,III), generally in patients with glomerular filtration rate (GFR) less than 25ml/min., significantly reduces the progression of kidney disease in the predialysis period and delays dialysis initiation.

Used for Prevention and Treatment of deficient protein metabolism in chronic renal insufficiency.

Storage conditions

Store in cool, dry place. Keep the medicine out of reach of children


CONIRON (Iron sucrose injection USP)
Composition

Each 5 mL ampoule contains: Ferric Hydroxide in complex with Sucrose equivalent to Elemental Iron 100 mg

Description

Iron sucrose is a dark brown liquid, non transparent, sterile aqueous solution. Iron Sucrose injection is an iron replacement therapy

Following intravenous (IV) administration, iron sucrose is dissociated into iron and sucrose and iron is transported as a complex with transferrin to target cells including erythroid precursor cells. The iron in the precursor cells is incorporated into haemoglobin as the cells mature into red blood cells.

Therapeutic Indications

For the treatment of iron deficiency anaemia in patients with chronic kidney disease (CKD).

To be administered intravenously either by slow injection or by drip infusion. The dosage of iron sucrose is expressed in mg of elemental iron. Each mL contains 20 mg of elemental iron.

Iron sucrose must not be used for intramuscular injection

Storage and Precautions

Store at room temperature below 25°C. Protect from light. Do not freeze.

Content should be visually inspected before use. The diluted solution must appear brown.


Description

Milipro is a unique composition of Pre & Probiotic (Synbiotic), intended to reduce the load of nitrogenous toxins in the body. When your body digests food, waste products are left behind in the bloodstream. Though toxic, this waste is usually filtered out of the blood by the kidneys and is passed as urine. However, when kidneys are damaged, the toxic waste builds up in the blood. Eventually, these toxins wind up in the colon. When the toxin levels become elevated, they can cause a host of serious health problem.

The mechanism of action of synbiotic is to decrease uremic toxin production and to improve renal function.

Storage Condition

Store in a cool, dry place, protected from light and moisture.


Composition

Each gram contains 20 mg mupirocin IP in an ointment base.


Description

Muprevent ointment is an RNA synthetase inhibitor antibacterial

Indications

Muprevent is indicated for the topical treatment of impetigo due to susceptible isolates of staphylococcus aureus and streptococcus pyogenes


Dosage

As per instructions of physician


Storage

Store in a cool place. Protect from direct sunlight. Do not freeze

A range of medicines to fight all kinds of infections be it bacterial or fungal in order to aid clinicians caring for critically ill patients, post-operative infections thereby helping in reducing mortality in ICU.


Composition
Each vial contains 100 mg Anidulafungin
Indication and clinical use

A single 200 mg loading dose should be administered on Day 1, followed by 100 mg daily thereafter. Duration of treatment should be based on the patient’s clinical response. Antifungal therapy should continue for at least 14 days after the last positive culture.

Renal and Hepatic Impairment No dosing adjustments are required for patients with mild, moderate or severe hepatic impairment.

No dosing adjustments are required for patients with any degree of renal insufficiency, including those on dialysis. Anidulafungin can be given without regard to the timing of hemodialysis

Storage condition for Unreconstituted Vial.

Vial should be stored at 2-8ºC.


Composition

Each vial contains Micafungin 50mg for intravenous (IV) infusion

Description:

Micafungin is an echinocandin group of antifungal. It inhibits the production of beta-1, 3- glucan, an essential component of fungal cell walls. Micafungin is administered intravenously.

Indication and clinical use

Usual Adult Dose for Esophageal Candidiasis 150 mg via IV infusion once a day Prophylaxis of Candida infections in hematopoietic stem cell transplant recipients Usual Adult Dose for Candidemia 100 mg via IV infusion once a day Duration of therapy

Treatment of patients with candidemia, acute disseminated candidiasis, Candida peritonitis and abscesses Usual Pediatric Dose for Esophageal Candidiasis

4 months or older: 30 kg or less: 3 mg/kg via IV infusion once a day Greater than 30 kg: 2.5 mg/kg via IV infusion once a day Maximum dose: 150 mg per day

Usual Pediatric Dose for Fungal Infection Prophylaxis 4 months or older: 1 mg/kg via IV infusion once a day Maximum dose: 50 mg per day

Prophylaxis of Candida infections in hematopoietic stem cell transplant recipients

Usual Pediatric Dose for Candidemia

4 months or older: 2 mg/kg via IV infusion once a day Maximum dose: 100 mg per day

Treatment of patients with candidemia, acute disseminated candidiasis, Candida peritonitis and abscesses

Renal Dose Adjustments

No adjustment recommended.

Liver Dose Adjustments

No adjustment recommended.

Dose Adjustments

Concomitant use of mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, voriconazole, itraconazole, amphotericin B, ritonavir, or rifampin: No adjustment recommended.

Dialysis Micafungin is not dialyzable. Supplementary dosing is not required following hemodialysis. Other Comments

Storage requirements:

Should be stored at room temperature 25 C, Ranges from 15 - 30 C.


Daptomycin
Composition
Daptomycin 500 mg lyophilized powder for reconstitution in a single-dose vial Description:

Daptomycin, a cyclic lipopeptide antibacterial agent derived from the fermentation of Streptomyces roseosporus.

Indications

Daptomycin is approved for use in adults for complicated skin and skin structure infections caused by Gram-positive infections, S. aureus bacteremia, and right-sided S. aureus endocarditis.

Dosage Skin Infections

4 mg/kg IV infusion q24hr for 7-14 days

Staphylococcus Aureus Bacteremia (Including Endocarditis)

6 mg/kg IV infusion q24hr for at least 2-6 weeks

Complicated Skin & Skin Structure Gram-Positive Bacterial Infections

6 mg/kg IV q24hr for 2-4 weeks

Storage Condition

Store at refrigerated temperatures, 2 to 8ºC (36 to 46ºF)


Composition

Each vial contains Teicoplanin 200 mg & 400 mg Powder for reconstitution and I.V. / I.M. use only.

Description

Teicoplanin is a glycopeptides antibiotic that has shown in vitro bactericidal activity against both aerobic and anaerobic gram-positive organisms. It is active against staphylococci (including those resistant to methicillin and other β-lactam antibiotics), streptococci, enterococci, Listeria monocytogenes, corynebacteria and gram-positive anaerobes including Clostridium difficile and peptococci.

Indications

Teicoplanin is indicated in adults and in children

Complicated skin and soft tissue infections, Bone and joint infections, Hospital acquired pneumonia, Community acquired pneumonia, complicated urinary tract infections, Infective endocarditis, Peritonitis associated with continuous ambulatory peritoneal dialysis (CAPD), Bacteremia that occurs in association with any of the indications listed above.

Teicoplanin is also indicated as an alternative oral treatment for Clostridium difficile infection-associated diarrhoea and colitis.

Teicoplanin may be used for antimicrobial prophylaxis in orthopaedic surgery at risk of Gram-positive infection.

Dosage Adult or elderly patients with normal renal function

Prophylaxis 400 mg intravenously as a single dose at induction of anesthesia Moderate infections: Skin and soft tissue infection, urinary tract infection, lower respiratory tract infection.

Loading dose: One single i.v. or i.m. injection of 400 mg on the first day Maintenance dose:A single i.v. or i.m. injection of 200 mg daily Severe infections: Joint and bone infection,Septicemia, endocarditis

Standard doses of 200 and 400 mg equate respectively to mean doses of 3 and 6 mg/kg. In patients weighing more than 85 kg it is recommended to adapt the dosage to the weight following the same therapeutic schedule: moderate infection 3mg/kg, severe infection 6 mg/kg

In the treatment of antibiotic-associated diarrhoea caused by Clostridium difficile: one oral dose of 200 mg twice a day.

Children (2 months and above) For severe infections and neutropenic patients

The recommended dose is 10 mg/kg every 12 hours for the first three doses; thereafter a dose of 10 mg/kg should be administered by either intravenous or intramuscular injection as a single dose each day.

For moderate infections

The recommended dose is 10 mg/kg every 12 hours for the first three doses; thereafter a dose of 6 mg/kg should be administered by either intravenous or intramuscular injection as a single dose each day.

Neonates

The recommended dosage regimen for neonates is a loading dose of 16mg/kg followed by a daily dose of 8 mg/kg.

In continuous ambulatory periotoneal dialysis

After a single loading IV dose of 400 mg if the patient is febrile, the recommended dosage is 20 mg/L per bag in the first week, 20 mg/L in alternate bags in the second week and 20 mg/L in the overnight dwell bag only during the third week, feverish patients must also take an I.V. loading dose of 400 mg of Teicoplanin, feverish patients must also take an I.V. loading dose of 400 mg of Teicoplanin.

Teicoplanin remains stable in solutions for peritoneal dialysis (1.36% or 3.86% dextrose). These solutions must not be kept for more than 24 hours.

Adults and elderly patients with renal insufficiency

For patients with impaired renal function, reduction of dosage is not required until the fourth day of Teicoplanin treatment.

In mild renal insufficiency:

Creatinine clearance between 40 and 60mL/min, Teicoplanin dose should be halved, either by administering the initial unit dose every two days, Creatinine clearance less than 40mL/min and in haemodialysed patients, Teicoplanin dose should be one third of the normal either by administering the initial unit dose every third day, or by administering one third of this dose once a day. Teicoplanin is not removed by dialysis.